ECE2010 Poster Presentations Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) (125 abstracts)
Sub-acute tumour debulking with somatostatin analogues in newly diagnosed acromegaly due to macroadenomas
Cristina Olarescu 1, , Øystein Husby 1 , Ansgar Heck 1 , Geir Ringstad 2 , Jon Terje Ramm-Pettersen 3 , Anders Palmstrøm Jørgensen 1 & Jens Bollerslev 1
1Section of Endocrinology, Rikshospitalet-Oslo University Hospital, Oslo, Norway; 2Department of Radiology, Rikshospitalet-Oslo University Hospital, Oslo, Norway; 3Department of Neurosurgery, Rikshospitalet-Oslo University Hospital, Oslo, Norway; 4University of Medicine and Pharmacy, ‘Iuliu Hatieganu’, Cluj-Napoca, Romania.
Background: Surgery is accepted as first line treatment of somatotroph macroadenomas with involvement of the optic chiasm. However, during recent years somatostatin analogues (SA) have increasingly been used as primary treatment improving ultimate cure rate, as SA’s have anti-proliferative effects in most tumours. We demonstrate here positive effect of subacute/acute SA treatment on tumour shrinkage and chiasm decompression in two recently diagnosed acromegalic patients.
Patients and results: Two female patients (P1 and P2) with newly diagnosed acromegaly due to GH secreting macroadenomas are presented. Both tumours were invasive, unable to be cured by direct surgery, and were compressing the optic chiasm. Ophthalmologic examination revealed slight temporal and nasal visual field defects but without vision affection. Both responded extensively on octreotide test (50 μg): GH decreased from 64.7 to 1.8 mUI/l (96%), (P1) and from >120 to 37 mUI/l, (P2). Both patients were treated primarily with subcutaneous SA, under very close follow up.
P1 was treated with 3×50 μg octreotide/day (for 15 days) and P2 received first 3×50 μg octreotide/day (for 4 days) then 3×100 μg octreotide/day (for 8 days). The table shows patients’ pre-treatment and post-treatment characteristics.
| P1 pre-T | P1 post-T | P2 pre-T | P2 post-T | |
| GH mean (day curve) (mUI/l) | 97.6 | 2.44 | >120 | 78 |
| IGF1 (nmol/l) | 135 | 16 | >208 | 149 |
| Tumour volume (mm3)/(% of decreasing) | 2858 | 2231/(21.4) | 6481 | 5043/(21.9) |
| Chiasma compression/visual filed defect | ++/+ | −/+ | ++/++ | −/? |
Discussion and conclusion: We present selected cases of newly diagnosed acromegaly with slight visual field defects, impractical to be cured by direct surgery. Both were successfully treated primarily with SA’s under close and careful follow-up, followed by significant tumor volume reduction and consequently relieve of the optic chiasm. We suggest that SA treatment is a possibility in selected cases for sub-acute debulking.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more